Prise en charge du cancer pulmonaire non a petites cellules

[en] Surgery, chemotherapy, radiotherapy and "biological" treatment are differently used in the treatment of non small cell lung cancer. Surgery is the cornerstone of the stages I-II treatment; chemotherapy is dominant in the treatment of metastatic stage, but is more and more used in earlier stages. A large discussion is still open for advanced non metastatic stages, even if the association of the 3 major modalities is extensively studied. We discuss our position in this setting.

Disciplines :

Oncology
Cardiovascular & respiratory systems

Author, co-author :

Bosquee, Léon ; Centre Hospitalier Universitaire de Liège - CHU > Pneumologie-Allergologie

Frusch, Nicolas ; Centre Hospitalier Universitaire de Liège - CHU > Frais communs médecine

Louis, Renaud ; Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie

Language :

French

Title :

Prise en charge du cancer pulmonaire non a petites cellules

Alternative titles :

[en] Update in Treatment of Non Small Cell Lung Cancer

Publication date :

29 August 2007

Journal title :

Revue Médicale Suisse

ISSN :

1660-9379

Publisher :

Medecine et Hygiène, Switzerland

Volume :

Issue :

122

Pages :

1890-5

Additional URL :

http://www.medecinehygiene.ch/mh/menu/maisons_d_editions/medecine_et_hygiene/revue_medicale_suisse

Available on ORBi :

since 23 March 2009

Statistics

Number of views

175 (10 by ULiège)

Number of downloads

7 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-6.
Koike T, Tsuchiya R, Goya T, et al. Prognostic factors in 3315 completely resected cases of clinical stage I non-small cell lung cancer in Japan. J Thor One 2007;2:408-13.
Cahan WG. Radical lobectomy. J Thorac Cardiovasc Surg 1960;39:555-72.
* Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1N0 non-small cell lung cancer. Ann Thorac Surg 1995;60:615-23.
** Nakamura H, Kawasaki N, Tagushi M, Kabasawa K. Survival following lobectomy vs limited resection for stage I lung cancer: A meta-analysis. BJC 2005;92:1033-7.
* Okada M, Yoshikawa K, Hatta T, Tsubota N. Is segmentectomy with lymph node assessment an alternative to lobectomy for non-small cell lung cancer of 2 cm or smaller ? Ann Thorac Surg 2001;71:956-61.
Kodama K, Doi O, Higashiyama M, Yokouchi H. Intentional limited resection for selected patients with T1N0M0 non-small-cell lung cancer: A single-institution study. J Thorac Cardiovasc Surg 1997;114:347-53.
** PORT Meta-analysis trialists group. Postoperative radiotherapy in non-small-cell lung cancer: Systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998;352:257-63.
Scagliotti GV, Fossatti R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II or IIIa non-small-cell lung cancer. JNCI 2003;95:1453-61.
Arriadaga R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60.
Waller D, Peake RJ, et al. Chemotherapy for patients with non-small-cell lung cancer: The surgical setting of the big lung trial. Eur J Cardiothorac Surg 2004;26:173-82.
Strauss GM, Herndon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following ressection in stage Ib non-small-ceff lung cancer: Report of cancer and leukemia group B (CALGB) protocol 9633. J Clin Oncol 2004;22:621S. Abstract 7019.
Barlesi S. Les traitements postopératoire des cancers bronchiques non à petites cellules réséqués. Rev Mal Respir 2006;23:16S47-16S53.
Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. Observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97.
Douillard J, Rossel R, Delena M, et al. (OBS) in completely resected (stage I-III) non-small-cell lung cancer patients: Final results after 70-month median follow-up. J Clin Oncol 2005;23:624S. Abstract 7013.
* Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell Lung Cancer. J Clin Oncol 2002; 20:247-53.
Berghmans T, Paesmans M, Meert AP, et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: Results of a meta-analysis of the literature. Lung Cancer 2005;49:13-23.
Nakamura H, Kawasaki N, Tagushi M, Kabasawa K. Role of preoperative chemotherapy for non-small-cell lung cancer: A meta-analysis. Lung Cancer 2006;54:325-9.
Robínson LA, Wagner H, Ruckdeschel C. Treatment of stage III. A non-small-cell lung cancer. Chest 2003;123;202-20.
Martin LW, Correa AM, Hofstetter W, et al. The evolution of treatment outcomes for resected stage IIIa non-small-cell lung cancer over 16 years at a single institution. J Thorac Cardiovasc Surg 2005;130:1601-10.
Rosell R, Gomez-Godina J, Camps C, et al. A randomized trial comparing preoperative chimiotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330:153-8.
Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in respectable stage IIIa non-small-cell lung cancer. J Natl Cancer Inst 1994;86:673-80.
Betticher DC, Hsu Schmitz SF, Tosch M, et al. Mediastinal lymph nodes clearance after docetaxel cis-platine neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIa pN2, non-small-cell lung cancer: A multicenter phase II trial. J Clin Oncol 2003;21:1752-9.
Hennequin C, Girard N, Mornex F. Chirurgie et chimioradiothérapie dans les carcinomes bronchiques de stade IIIa. Cancer/Radiothérapie 2006;10:477-83.
Senik M, Riesenbeck D, Linder A, et al for the German Lung Cancer Cooperative Group. Preoperative chemotherapy with and without additional radiochemotherapy; Benefit and risk for surgery offstage III non-small cell lung cancer. Eur J Cardiothorac Surg 2004;26:1205-10.
Albain K, Swann R, Rusch V, et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIa (pN2) non-small cell lung cancer: Outcomes update of North American Intergroup 0139 (RTOG 9309). Proceed Am Soc Clin Oncol 2005;24:7624s abstract.
Van Meerbeck J, Kramer G, Van Schil P, et al. A randomized trial of radical surgery versus thoracic radiotherapy in patients with stage IIIa N2 non-small cell lung cancer after response to induction chemotherapy (EORTC 08941). Proceed Am Soc Clin Oncol 2005;24:7624S (abstract)
Oilman RO, Seagren SL, Popert KJ, et al. A randomized trial of induction chemotherapy plus high dose radiotherapy versus radiation alone in stage III non-small cell lung cancer. N Engl J Med 1990;323:940-5.
* Non-Small cell lung cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non small cell lung cancer. A meta-analysis. Cancer 1995;76:593-601.
Penland SK, Socinski MA. Management of unresectable stage III non small cell lung cancer: The role of combined chemoradiation. Semin Radiat Oncol 2004;14:326-34.
** Rowell NP, O'Rourke NP. Concurrent chemoradiotherapy in non-small cell lung cancer (review). The Cochrane collaboration and published in the Cochrane Library 2005, issue 3.
Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis. JNCI 2007;99:847-57.
Cornella P, Frasci G, Panza N, et al. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: Interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol 2000;18:1451-7.
** Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002;346:92-8.
Fossella F, Pereira JR, von Pawel J, et al. Randomized multinational, phase III study of docetaxel plus platinum combination vs vinorelbine plus cisplatin for advanced non-small cell lung cancer: The TAX 326 Study Group. J Clin Oncol 2003;21:3016-24.
Sheperd FA, Dancey J, Ramalu R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103.
Anna N, Sheperd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97.
Sheperd FA, Rofrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
Kosmidis PA, Dimopoulos MA, Syrigos K, et al. Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: A prospective randomized phase II study of the Hellenic Cooperative Oncology Group. J Thorac Oncol 2007;2:135-40.
Blackhall FH, Bhosle J, Thatcher N. Chemotherapy for advanced non-small cell lung cancer patients with performance status 2. Curr Opin Oncol 2005;17:135-9.
Thatcher N, Chang A, Parikh P, et al. Results of a phase III placebo controlled study (ISEL)of gefitinib (Iressa) plus bst supportive care (BSC) in patients with advanced non-small cell lung cancer who had received one or two prior chemotherapy regimens (abstract). Proc Am Assoc Cancer Res 2006;46: LB6.
Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: A phase III trial Intact-1. J Clin Oncol 2004;22:777-84.
Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: A phase III trial Intact-2. J Clin Oncol 2004;22:785-94.
Herbst RS, Prager D, Hermann R, et al. Tribute: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-9.
Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib hydrochloride (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-smalt-cell lung cancer. Proc Am Soc Clin Oncol 2004:A7010.
Kelly K, Herbst RS, Crowley JJ, et al. Concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in advanced non-small-cell lung cancer (NSCLC): Randomized phase II selectionnal trial SWOG 0342 (abstract). Proc Am Soc Clin Oncol 2006;24:367s.